We combined trastuzumab X-body with TLR7/8 agonist (Figure 6F), the combination therapy improved tumor inhibition activity and produced 6 days and 9 days tumor growth delay compared to X-body and R848 treatment alone (Figure 6G, H). This evidence concerns the gene TLR7 and neoplasm.